0 results

Closing a financing gap

The Crossover strategy launched in April 2018, completing Sofinnova's investment platform by enabling it to invest across the life-sciences value chain, from seed stage to later-stage.

We invest across all biotech sectors, focusing on companies with game-changing science that has initial proof of concept.

2018Sofinnova Crossover I€445 million
  • Close: 2018

    Fund: Sofinnova Crossover I

    AMT: €445 million

"Sometimes you need to have a significant stake in a company and be in the board room to really drive some of the strategy and the changes it may need."

"Rather than thinking about Series B or what round it is, we buy into companies depending on their clinical stage development and proof of concept."

"It is exciting to help companies find that next gear of growth as they bring new medicines to market.”

"For the companies we invest in, we spend months looking at clinical programs, intellectual property, manufacturing, management, the board, every detail. The Sofinnova Partners network helps with all of this."


Fund iteration
Deal lead

Join our mailing list

Keep up to date with our latest news.

Thanks for submitting the form. You are now subscribed to Sofinnova Partners news alerts.An error happened. Please try again later.